TRIB VS LLY Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

TRIB
10/100

TRIB returned -60.18% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

LLY
100/100

LLY returned 68.15% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

TRIB
83/100

3 analysts offer 12-month price targets for TRIB. Together, they have an average target of 0, the most optimistic target put TRIB at 0 within 12-months and the most pessimistic has TRIB at 0.

LLY
68/100

22 analysts offer 12-month price targets for LLY. Together, they have an average target of 391, the most optimistic target put LLY at 673 within 12-months and the most pessimistic has LLY at 236.

Sentiment

TRIB
67/100

TRIB had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 5.22 posts, 3.44 comments, and 2.83 likes per day.

LLY

"Sentiment" not found for LLY

Technicals

TRIB
11/100

TRIB receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

LLY
57/100

LLY receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

TRIB
10/100

TRIB has missed earnings 10 times in the last 20 quarters.

LLY
10/100

LLY has missed earnings 7 times in the last 20 quarters.

Profit

TRIB
48/100

Out of the last 20 quarters, TRIB has had 14 profitable quarters and has increased their profits year over year on 4 of them.

LLY
66/100

Out of the last 20 quarters, LLY has had 19 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

TRIB
50/100

TRIB has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

LLY
53/100

LLY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

Dividend

TRIB

"Dividend" not found for TRIB

LLY
100/100

LLY's most recent dividend was $0.57 per share, based on a share price of $588.54. It was a payout ratio of 50.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Trinity Biotech plc Summary

Nasdaq / TRIB
Healthcare
Medical - Diagnostics & Research
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Eli Lilly & Co. Summary

New York Stock Exchange / LLY
Healthcare
Drug Manufacturers - General
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.